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ABSTRACT
Kinetic models are increasingly relevant in medical research. In
systems biology, more than 10 years of experience with the develop-
ment of standards and tools to construct and analyse kinetic models
exists. This has supported the sharing of kinetic models, increased
their reuse, and thereby has helped to reproduce and validate sci-
entific results. Given this expertise, it seems natural to consider
the application and development of standards and tools to meet the
requirements of medical scientists.
In this paper, we discuss challenges and opportunities for stan-
dards and tools from systems biology in medical research, and we
suggest criteria for the safe use of simulations. We conclude that
standards, tools and infrastructure need to be extended to ensure
the quality, reliability and safety required when working with medical
and patient data. This will foster the adaptation of modelling in the
clinic, providing tools for improved diagnosis, prognosis and therapy.
Contact: dagmar.waltemath@uni-rostock.de
1 INTRODUCTION
In modern medicine, technologies complement conventional clin-
ical data with molecular and genetic information. Patient-specific
molecular profiling provides opportunities for earlier diagnosis,
more accurate prognoses and optimised therapeutic decisions [1].
The data generated from these new technologies have led to a rise
of computational approaches in medicine [2].
‘Personalised Medicine’ and ‘Systems Medicine’ are two terms
that are frequently used to capture this trend for interdisciplinary
approaches in which clinical research, molecular and cell biol-
ogy, medical informatics, bioinformatics, biostatistics and systems
biology approaches join forces. Personalised medicine uses marker-
assisted diagnosis and targeted therapies derived from an individ-
ual’s molecular profile and patient data [3]. Systems medicine aims
to bring computational models closer to the clinic to shed light on
the dynamic complexity of human physiology and disease [4]. In
this context, the focus has been on the modelling of phenomena,
where an understanding of processes (kinetics) is crucial. This in-
cludes the response of cells, tissues and organs to drugs [5]; the
∗to whom correspondence should be addressed
simulation of disease progression [6]; and the understanding of
mechanisms, as opposed to just predicting outcomes [7].
With new technologies available to provide the data to identify
and characterise disease relevant components, there is an increasing
demand for methodologies that enable us to study the interactions
of molecular and cellular components in a patient. Arguably, the
success of systems and personalised medicine relies then on the
application of kinetic models in the clinic [8].
The construction of such models requires an integration of clin-
ical and patient-specific molecular data with public databases such
as Ensembl [9] and ENCODE [10]. This process effectively brings
together the two worlds of basic research and clinical practice. For
this union to succeed, ontologies will play a crucial role. Standards
to encode information together with ontologies to unambiguously
characterise domain knowledge, form the basis for the development
of tools that can analyse kinetic models. These tools in turn support
the sharing and reuse of models, which is also a means to validate
results and generally improve reproducibility in medical research.
Here we illustrate the challenges that need to be overcome in
future work to achieve trustworthy systems that can be integrated
easily into a clinical environment. The structure of the remaining
sections of this paper is as follows. In section 2 , we outline the
challenges that exist when planning to use state-of-the-art systems
biology tools and standards in clinical environments. Following on
from that, in section 3 we suggest criteria that address the challenges
outlined and need to be taken into consideration when building clin-
ically applicable solutions. We present a summary of our findings in
the last section of this paper.
2 CHALLENGES IN APPLYING SYSTEMS
BIOLOGY STANDARDS AND TOOLS
2.1 Access to clinical data
Almost no clinical data sets are available for integration with
models, neither are these data sets sufficiently documented in a for-
malised manner. Consequently, the process of selecting clinical data
for a given model (and vice versa) is hindered. This is partly due
to patient data being sensitive, limiting its accessibility for analysis,
but mainly due to missing incentives, guidelines and requirements
to provide data access upon publication of clinical studies.
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Clinical data sets are required for testing as well as prediction
purposes. While a reoccurring complaint is the lack of suitable data
sets to test a model with, this problem is hard to overcome given
that patient data needs to be secured over unauthorised access at all
times or anonymised in a proper manner. Some efforts such as the
100,000 genome project conducted by Genomics England1 and the
openEHR2 project aim to provide access to structured, semantically
annotated clinical data for research purposes. However, the amount
of available data is still too limited to test models and computational
simulations reliably.
In practice, most research data are neither shared nor recycled
outside the original project team [11]. Models are instead being
developed and used within a single clinic, e. g. by collaborative
projects that incorporate clinical research groups and computational
biology groups located in the same institution. In these settings,
however, modelling has already been applied successfully, for
example to study melanoma resistance to immunotherapy [12].
2.2 Good quality models and documentation
In addition to relevant clinical data being accessible, it must be rep-
resented in a way that it can be integrated and interpreted by both
humans and machines. This requires a dialogue not only between
healthcare providers and researchers, but also with staff recording
the data and policy makers regulating patient data records.
Currently, the majority of published models are not available in
standard formats, and the model quality is not sufficiently doc-
umented. While promoting the reuse of such virtual experiments
would vastly improve the usefulness and relevance of computational
models in biomedical endeavours [13], even the computational code
underlying a model is often inaccessible. Without the ability of re-
producing the models, however, models cannot be exploited for
clinical use. SED-ML is a standard for the encoding of simulation
setups, the specification of possible parametrisations and the def-
inition of analyses [14]. However, SED-ML to date encodes only
for a subset of experiments performed in clinical research. Further
extensions are needed in the standard itself.
In addition, available models are not fully annotated, i.e. the
description of model components and parameters are missing, hin-
dering interpretation and integration with other models and clinical
data. Model provenance information is not kept, leading to misin-
terpretations and even irreproducibility of the original findings.
Ongoing efforts such as curation processes in BioModels3, or the
provision of fully reproducible archives of virtual experiments in
the Physiome Model Repository [15] or in the JWS Online database
[16] improve this situation. However, curation is very slow due to
the manual labour involved and seldom performed after a model has
been published. Moreover, concerted efforts for model validation,
annotation, and conversion into computable formats are lacking.
2.3 Standardised representation of models and data
The systems biology community developed a set of interoperable
standards for modelling in biology, including the Systems Biology
Markup Language (SBML), CellML, Synthetic Biology Markup





Markup Language (SED-ML), or BioPax [17]. As a consequence,
sharing and/or integrating models within communities is feasible.
However, model reuse across communities can be challenging, as
different standards are used for the representation and annotation of
the data.
Even within communities, there is no consensus on which ontolo-
gies to use for data and model representation. It is also not defined
to which degree of detail models and data need to be annotated, cre-
ating further obstacles to integrate models for simulation purposes.
Extensive cross-domain initiatives need to be built and are required
to take decisions on ontologies and standards that are not only con-
venient for model developers, curators and researchers, but that are
also practical (implementation, costs, etc.) in a clinical application
scenario.
2.4 Validated predictions in a clinical context
A major hurdle for the translation of computational models into
medical research is the difficulty to proof the efficiency and pre-
dictive value of the model. Every recommendation determined by a
clinical decision support system needs to be in line with the policies
for medical care providers as issued by the health authorities in the
respective country. In order to proof health economic efficiency, ex-
tensive, potentially double-blinded, clinical trials are required that
compare model-based treatment decisions with unsupported deci-
sions by clinical staff. These clinical trials have to span over all areas
of clinical application, i.e. cover different types of diseases as well
as ranges of treatments and patients in differing health conditions
to assess clinical safety. Every in silico model provides an esti-
mation of pathological processes and therefore naturally contains
errors. These errors can potentially lead to wrong treatment deci-
sions, which is why great care needs to be taken when transporting
systems biology models, standards and tools into clinical practice.
Sustained software support is equally important. Software libraries
for standards should to be stable, well-tested, and they should sup-
port the complete standard in correct manner. Such implementations
will facilitate the update of standards by the community and tool
developers and thus provide shareable data and models.
3 CRITERIA FOR REUSABLE SIMULATION
MODULES AND SEMANTIC DATA
The reproducibility and reusability of models and model-based re-
sults have been discussed in several assays over the past years
[8, 18]. One conclusion of these assays is that the reusability of sim-
ulation models needs to be ensured, before computational models
can be considered for predictive processes in the clinic. Four impor-
tant aspects that determine reusability are discussed in the following
subsections.
3.1 Semantic annotation via biomedical ontologies
An essential step to ensure reusability of models is a thorough se-
mantic annotation to biomedical ontologies. An ontology formally
defines concepts and relations between concepts in a knowledge
domain [19]. In the context of this paper, semantic annotation de-
scribes the process of linking the entities and processes of a model
to terms in relevant ontologies. These semantic descriptions allow
researchers and tools alike to describe the data used in experimental
studies and models. They enable not only the integration of different
types of data but also the reasoning over the data, thus connecting
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data items (or models) to existing knowledge. Systems biology es-
tablished a system for semantic annotations of models, using RDF
together with standardised relationships [20] and resources identi-
fiers [21]. Recently, composite annotations have been proposed as a
means to provide exact descriptions of the model entities [22].
In order to implement models in the clinic, the systems biology
data must be linked to biomedical data, biomedical measurements
and personalised patient data. An integration on the syntactical level
is not expressive enough to allow for automatisation, but integra-
tion on the semantic level holds the promise of overcoming this
limitation. Figure 1 illustrates the necessary steps for the seman-
tic integration of patient data, computational models, and external
data for the benefit of patients and clinical staff.
Many biomedical ontologies are maintained in online portals,
such as BioPortal or the Open Biomedical Ontologies (OBO)
Foundry web page, which provide search interfaces, web services,
version control, and mappings between ontologies [23, 24, 25].
However, different ontologies are used for a semantic representa-
tion due to e.g. differences in the medical systems used in dif-
ferent countries which requires reliable mappings between these
ontologies.
One effort addressing the mapping between terminologies and on-
tologies is the Unified Medical Language Systems (UMLS) [26],
which to date harmonises over 150 terminologies and ontologies4.
For example, the Human Phenotype Ontology [27], the International
Classification of Diseases 5 and SNOMED CT [28] are all integrated
in UMLS. While resources such as UMLS allow the transfer from
one ontology to the other, it is important to be aware that this process
of transfer largely depends on the quality of the mapping and the
quality of the annotations that have been assigned in the first place.
Moreover, as ontologies go through several development cycles, the
mappings need to be updated, which in itself can lead to a change in
the quality of the mapping and consequently the alignment of data
and models in clinical applications. Furthermore, research into the
direction of mappings and similarity measures for terms within and
across bio-ontologies should be taken into account [29]. For exam-
ple, it can be valuable to determine the similarity of data sets that
are annotated to different ontologies.
Another set of ontologies to consider for this endeavour are those
encoding information about model versions, as well as provenance
and evidence of data encoded in the model. For example, PROV-O
[30] is an ontology of provenance terms that could potentially be
adapted to attach provenance to model data. Similarly, the Prove-
nance, Authoring and Versioning Ontology (PAV) [31],can be used
to add provenance information for collected data and representations
chosen in simulation models/modules. Another effort going into
this direction is the Ontology of Biomedical AssociatioN (OBAN),
used for provenance information on disease-phenotype associations
text mined through EuropePMC6 [32]. Furthermore, the Evidence
Ontology (EVO) [33] captures terms that can be used to trace
biomedical evidence in data as well as models. Despite these on-
going efforts, further work is needed to allow for the integration of
computational models with a variety of independent data resources.
4 https://www.nlm.nih.gov/pubs/factsheets/umls.
html, accessed 14 June 2016
5 http://www.who.int/classifications/icd/en/
6 http://europepmc.org/
3.2 Generation of safe simulation modules
Reusability depends on the availability of all model-related data [8].
For studies performed by medical researchers, it is particularly im-
portant to provide full documentation of safe parameter ranges and
test case scenarios. This requires tailor-made standards for report-
ing. The data description must ensure that it is straightforward to
interpret the output from simulation modules without an expertise
in modelling.
In this context, a simulation module encapsulates a computational
model that has been tested, documented, annotated, and certified to
meet safety requirements. A module suitable for inclusion into a
diagnostic tool needs to provide extensive documentation and safe,
standardised software interfaces (e. g. for resetting simulation pa-
rameters or accessing and interpreting simulation results; see more
details section 3.4). The requirements for documentation of a model
are clearly defined in a Minimum Information guideline (MIRIAM)
[34]. We argue that the documentation of a simulation module for
medical research needs to be extended to also cover information on
applicable virtual experiments, allowed applications, and conditions
under which the data are applicable in simulations.
In addition to these factors, the development, testing and man-
agement of software used for medical purposes will need to follow
rules issued by regulatory agencies to ensure the safety of patients
and their related data. As medical software Apps have become more
prevalent, guidance has been developed by a number of national
agencies including Germany (“Medizinproduktegesetz”)7 the US 8
and the UK 9. These include definitions of what software constitutes
a “medical device” and which regulations apply. However frame-
works to regulate sophisticated software systems for medicine, such
as simulation modules, will need considerably more development.
3.3 Testing procedures to ensure safety
Due to the sheer amount of data necessary to model the physiology
of a human being, the development of future diagnostic tools will
rely on previously developed, standardised simulation modules and
on thorough semantic annotation. Before models and consequently
modules can be consulted in medical predictions they need to be
tested thoroughly. This is, in theory, possible for a subset of models
in systems biology. For example, all models in the curated branch
of BioModels should be able to reproduce at least one behavior
observed and described in the reference publication.
For a module to be considered safe in a clinical environment, the
encapsulated model predictions must be medically reliable, i.e. they
must not only capture the underlying disease mechanisms but also
adapt to the uniqueness of each individual patient. This requirement
entails that the error rate for predictions needs to be very small and
under no circumstances can exceptions lead to failure in the inter-
mediate computation. Due to the diversity of data that is included
into a model, physical units, error ranges and data mappings have










Figure 1. A) Illustration of the integration process of computational models and data from different sources. The integration strongly relies on the availability
and detail of the ontologies used for the semantic annotations. User interfaces need to provide access to the simulation modules, but restrict the change of
parameters to ranges that are safe w.r.t. a clinical application. SBML and CellML are standards used to encode models in a computable format. Electronic
Health Records (EHRs) refers to any data recorded in a hospital or GP practice. B) Example workflow for the application of a simulation module to the
prediction of the Galactose Elimination Capacity (GEC), a key liver function parameter. Semantically annotated patient data is used as input to the simulation
module based on the defined module interface. The module performs individual predictions and risk estimation based on the input data which can be evaluated
within the context of the reference ranges of the module. A proof-of-principle is available at https://www.livermetabolism.com/gec_app/. The
example model is a regression model for the prediction of hepatic galactose clearance based on the independent variables gender, age, height, and weight as
input parameters. The predicted GEC value and its variability (based on the uncertainty of the model prediction) are than used for the classification of the
subject into healthy or diseased with the measured GEC value. Within the figure the presented key challenges (C) and important solutions (S) for systems
biology standards and tools and medical research are marked: (C1) Access to clinical data. High quality clinical data must be integrated with the models.
These are required for validation and for prediction; (C2) Good quality models and documentation. Requirement for representation in standard formats and
description of model components and parameters; (C3) Standardised representation of models and data; (C4) Validated predictions in a clinical context.
Efficiency and predictive value of the model have to be shown. Policies of medical health care providers have to be fullfilled; (C5) Detailed documentation of
virtual experiments. Simulation settings are necessary to reproduce and verify the results; (S1) Semantic annotation via biomedical ontologies; (S2) Generation
of safe simulation modules; (S3) Testing procedures to ensure safety. Functional curation of models; (S4) Standardised and secure software interfaces. Safe
simulation of models via validation of input parameters and definition of allowed values;
data to be simulated with the module matches the requirements of
model parameters such that a reliable prediction can be ensured.
For this purpose, standardised tests need to be in place and con-
tinuously be passed throughout development. The electrophysiology
web lab [35] is one example of a web-based tool to check the reli-
ability of models relating to the physiology of the heart. It features
a set of published models in CellML format, and applies to them
several virtual experiments. The tests check how each model re-
produces the expected behavior of a real heart under a variety of
conditions. This procedure is referred to as functional curation of
the model [36].
Tests facilitate model evaluation and are thus an important com-
ponent of a module. The test data consists of simulation inputs and
outputs, which allow users to evaluate predictive error, sensitivity
and specificity of a module. Furthermore, users require access to the
tests with which the parameter ranges and prediction outcomes have
been assessed during model development.
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The documentation released with a simulation module should de-
tail how simulation results are to be correctly interpreted. This is
particularly relevant for the classification of results in terms of quan-
tiles within patient cohorts. In order to verify whether a module is
safe for use, information detailing the history, developer(s), input
data and test results is strictly necessary. Only if this information is
provided one can evaluate if the latest version of a module is safe for
application and how the changes made over time have affected the
error rates of predictions as well as edge-cases in simulation scenar-
ios. Systems biology already offers tools for model version control
(e. g., [37]). However, we note that the potential of model prove-
nance has not yet been fully explored, and the description of model
parameters as well as a model’s quality (in terms of applicability
and reliability) is so far neither satisfactory nor standardised.
3.4 Standardised and secure software interfaces
In order to apply modules in clinical practice, standardised software
interfaces are required that enable the safe simulation of models (e.g.
through restricted parameter ranges), validation of input parame-
ters, support for allometric scaling (of parameters like organ sizes
or blood flow), and the evaluation of simulation results in terms of
confidence intervals.
It is not unlikely that a model used through a diagnostic tool is
administered by a clinician, nurse or other medical staff. The simu-
lation mode must hence include a safe mode in which only defined
properties of the model/module can be adapted. However, these de-
fined properties need to cover, at the same time, the uniqueness of
each patient so that the simulation can be truly personalised. An
adaptation of the above web lab can help to provide clinicians with
an overview of possible behaviors of a system given different sets of
patient data and clinical investigations.
Software tools such as the Taverna Workflow Suite [38] or Galaxy
[39] are used for various data analysis tasks in Bioinformatics. Once
constructed, the workflows are reusable. Executable protocols can
be shared, reused and repurposed. Similarly, high-quality work-
flows could be provided for standard procedures in the clinic that
involve virtual experiments. Tested and trusted workflows can safe
clinicians time as they automatise processes that otherwise would
require a long time to specialise in.
Moreover, tool and model developers have to safeguard the data
that is used as input to the computational model so that patient data
cannot be used for other purposes than the treatment of this patient.
Otherwise obtaining consent from patients to employ their data for
medical purposes will be impossible. There is an arguable potential
that the models could be improved over time as the patient data in
itself can help tweaking model parameters but this would have to be
covered by each patient’s consent.
4 CONCLUSION
With kinetic models being increasingly used and reused for the pre-
diction of disease risks, the monitoring of disease progression, or
for drug development, the quality and reliability of models becomes
a major concern. In this situation, medical research can benefit from
the experiences in systems biology, by incorporating existing stan-
dards, tools and infrastructure. Standards and standard-compliant
tools increase the exchangeability of models, and enable researchers
to reproduce published results. As computational models can be
readily parameterised with individual patient and cohort data, they
are well-suited for personalisation. Moreover, the models can be
embedded in pharmacokinetics and pharmacodynamics applications
used during drug development.
However, before modeling can be fully incorporated into medical
workflows, additional requirements should be met. Among these
are further standards to represent the provenance of a model and to
document valid parameter ranges under certain conditions. Further-
more, solutions for high-quality annotation of models and for the
curation of data need to be developed. Other challenges, like the
representation of uncertainties, restricted model changes and per-
sonalisation are yet unsolved and have to be addressed in future
research. A specific focus of future works should be on the defi-
nition of a minimal semantic interface that patient data has to fulfill
for a model to be applicable, i. e., a minimal set of semantically en-
coded data the model requires as input. For instance, in the case of a
regression model, all independent variables of the model must exist.
Finally, models used in the clinic need to fulfill safety require-
ments and adhere to data privacy guidelines. For example, at no
point would it be acceptable to mix data from several patients and
give a patient or other unauthorised staff access to patients’ data.
We conclude that systems biology research focuses on the de-
velopment of (predictive) models. These models are mainly set in
a research environment and use batch samples and flexible time
tables. Many of the achievements towards reproducibility of sim-
ulation studies in systems biology can be reused to establish an
infrastructure for reusable models in the clinic. However, the ex-
isting infrastructure needs to be evaluated thoroughly, and it needs
to be extended to meet clinical standards when working with patient
data.
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